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Abstract
Background: To summarize the relationship between type 2 diabetes mellitus (T2DM) and risk of colorectal
adenomas (CRA), we performed a meta-analysis of observational studies.
Methods: To find studies, we searched PubMed, Embase, the Cochrane Library, Web of Science and conference
abstracts and related publications for American Society of Clinical Oncology and the European Society of Medical
Oncology. Studies that reported relative risks (RRs) or odds ratios (ORs) with 95 % confidence intervals (CIs) for the
association between T2DM and risk of CRA were included. The meta-analysis assessed the relationships between
T2DM and risk of CRA. Sensitivity analyses were performed in two ways: (1) by omitting each study iteratively and
(2) by keeping high-quality studies only. Publication bias was detected by Egger’s and Begg’s tests and corrected
using the trim and fill method.
Results: This meta-analysis included 17 studies with 28,999 participants and 6798 CRA cases. We found that T2DM was
a risk factor for CRA (RR: 1.52; 95 % CI: 1.29–1.80), and also for the advanced adenoma (RR: 1.41; 95 % CI: 1.06–1.87).
Patients with existing T2DM (RR: 1.56; 95 % CI: 1.16–2.08) or newly diagnosed T2DM (RR: 1.51; 95 % CI: 1.16–1.97) have a
risk of CRA. Similar significant results were found in retrospective studies (RR: 1.57; 95 % CI: 1.30–1.89) and population
based cross-sectional studies (RR: 1.46; 95 % CI: 1.21–1.89), but not in prospective studies (RR: 1.27; 95 % CI: 0.77–2.10).
Conclusions: Our results suggested that T2DM plays a risk role in the risk of developing CRA. Consequently, medical
workers should increase the rate of CRA screening for T2DM patients so that they can benefit from behavioural
interventions that can help prevent the development of colorectal cancer. Additional, large prospective cohort studies
are needed to make a more convincing case for these associations.
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Background
Diabetes mellitus (DM) is the fourth or fifth leading
cause of death in developed countries and one of the
biggest threats to human health worldwide [1]. More
than 90 % of all DM is type 2 diabetes mellitus (T2DM)
[2, 3]. Colorectal cancer (CRC) is the third most com-
mon cancer in the world. Colorectal adenoma (CRA)
(also known as adenomatous polyp and always found by
colonoscopy screen [4]) is a prevalent precancerous
lesion that can lead to CRC through the adenoma–car-
cinoma sequence [5].
Research on risk factors for CRA has focused on sev-
eral epidemiological factors, including smoking [6], alco-
hol consumption [5], body mass index [7], physical
activity [8], and calcium intake [9]. Recent research on
patients with diabetes suggested that insulin therapy and
diabetes itself may increase the risk of CRC [10–12].
However, the association between T2DM and the risk of
CRA risk has not yet been fully established. Some re-
searchers asserted that there were no overall associations
between T2DM and CRA risk [13–16], while others re-
ported a higher risk [17–20]. To further examine these
findings and provide evidence of association between
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T2DM and risk of CRA risk, we performed a meta-
analysis about T2DM on the risk of CRA.
Methods
Literature search
Two investigators (FY and YG) independently conducted
a systematic literature searches on January 10, 2016 in
PubMed, Embase, the Cochrane Library and Web of
Science without limiting the publication date range. The
following search terms were used: (diabetes mellitus OR
diabetes OR diabetic OR glucose) AND (colorectal OR
colon OR rectal) AND (adenomas OR adenoma OR ad-
enomatous OR polyp). No language restrictions and any
other limitations were imposed. Conference abstracts on
the websites of American Society of Clinical Oncology’s
(ASCO) and the European Society for Medical Oncology’s
(ESMO) annual meetings were also searched, along with
the reference lists of the identified publications. Additional
file 1 includes the complete searching process.
The titles and abstracts of all of the studies from the
searches were screened independently by three reviewers
(FY, YG and JF). To be included in this meta-analysis,
studies had to be at least one of the following criteria:
(1) retrospective or perspective observational study of
the association between diabetes mellitus and CRA, or
(2) a study reporting the relative risks (RRs) or odds
ratios (ORs) for T2DM on CRA with 95 % confidence
intervals (95 % CIs) adjusted for gender, age, or other
factors. Studies reporting on the CRA recurrence were
excluded.
Data extraction
Data extraction was performed by three reviewers (FY,
YG and WH), and verified independently for accuracy
by a forth reviewer (JH). The following information was
collected for each study: title and author, publication
year, population, location, sample size, proportion of
males and covariates controlled for by matching or
multivariate analysis. For studies that reported several
multivariate adjusted ORs, the effect estimate that ad-
justed for the maximum potential confounders was se-
lected. Two investigators (FY and ZJ) conducted a
quality assessment using the 9-star Newcastle-Ottawa
Scale (NOS) [21], which was verified by a third investi-
gator (YG). We considered studies with a NOS score of
seven or more to be high-quality studies. The study se-
lection process was based on the Meta-analysis of Ob-
servational Studies in Epidemiology (MOOSE)
guidelines [22] and is described in Additional file 2.
Statistical analysis
We examined the relationship between T2DM and CRA
risk on the basis of the adjusted RRs and ORs and corre-
sponding 95 % CI published in each study. A fixed
effects model was used to estimate the pooled RR and
OR with 95 % CIs if there was no evidence of heterogen-
eity; otherwise, a random effect model was used [23, 24].
Because the incidence of CRA is low, the ORs in retro-
spective studies approximate the RRs [25, 26]. Heterogen-
eity between the studies was evaluated by the chi-square
test and I-squared (I2) statistic [23]. Statistical heterogen-
eity was considered significant when p < 0.10 [27].
Several methods were used to test and adjust for po-
tential publication bias. Visual inspection of funnel plots
was performed, and the Egger’s regression test [28] and
Begg’s test [29] were used. Where publication bias
existed, we used the trim and fill method to correct it
[30]. Subgroups analyses by gender, adenoma subsite,
and study type were performed to explore the potential
heterogeneity among the included studies. Sensitivity
analyses were performed in two ways: (1) by excluding
each study iteratively from the meta-analysis and (2) by
keeping high-quality studies only.
All statistical tests were two-sided and regarded as sta-
tistically significant at p < 0.05 Stata (Version 11.0; Stata
Corp, College Station, TX) was used for all analyses.
Results
Study characteristics
Until January 10, 2016, 2522 records were retrieved by
using our search strategy. After reviewing the titles and
abstracts, 113 articles were further evaluated by review-
ing the full texts. Of those remaining articles, we ex-
cluded studies that : (1) reported the data of adenoma
recurrence were excluded [31, 32], (2) did not reported
the RRs of getting CRA separately but mixed CRC and
CRA patients [31], and (3) discussed the relationship be-
tween metformin [33] or insulin use [34] and CRA. We
identified 17 studies that met all of our criteria [13–20,
35–44], including four conference abstracts [36, 37, 43,
44]. Figure 1 provides a flow chart of study selection.
The final studies included 28,999 participants and 6798
CRA cases and 11 were rated as high-quality. Four of
the conference abstracts rated less than seven stars due
to insufficient information about their research. Table 1
includes the general characteristics of the included
studies.
Diabetes and risk of colorectal adenoma
The summary RR of diabetes on CRA was statistically
significant (RR: 1.52; 95 % CI: 1.29–1.80). Evidence of
the heterogeneity was identified (I2 = 65.6 %, P < 0.001).
Figure 2 shows the results.
Subgroup analysis
As shown in Table 2, we conducted subgroup analyses
based on multiple factors, including sub-site of aden-
oma, geographic region, gender, and study type. The
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results showed that advanced adenoma was significantly
associated with T2DM (RR: 1.41; 95 % CI: 1.06–1.87).
However, a similar effect was not detected for prox-
imal, distal, or colon adenoma. No evidence indicated
significant associations between T2DM and CRA by
gender, i.e., males (RR: 1.36; 95 % CI: 0.99–1.80) or
females (RR: 1.29; 95 % CI: 0.76–2.17). he relation-
ships between T2DM and CRA risk was significant in
Europe (RR: 1.27, 95 % CI: 1.02–1.57), the USA (RR:
1.69; 95 % CI: 1.14–2.51) and Asia (RR: 1.57; 95 %
CI: 1.21–2.05). A significant increase in risk was
found in retrospective studies (RR: 1.57; 95 % CI:
1.30–1.89) and not in prospective studies (RR: 1.27;
95 % CI: 0.77–2.10).
Sensitivity analysis
Sensitivity analysis indicated that no single study dra-
matically influenced the pooled RR. The results are
shown in Fig. 3. Regardless of which study was omit-
ted, the summary RRs were always greater than one.
Similarly, Table 2 shows that excluding low-quality
studies yielded results comparable with including all
studies (RR: 1.64; 95 % CI: 1.26–2.14).
Publication bias
The Begg’s rank correlation test (p = 0.001) and Egger’s
regression test (p = 0.003) results showed potential publi-
cation bias that is described in Fig. 4. Once corrected by
the trim and fill method [30], the result indicated that
the pooled effect size did not changed.
Discussion
This study indicated that patients with diabetes, espe-
cially type 2, have about 50 % increased relative risk of
developing CRA than non-diabetic individuals, regard-
less of their geographic location. Although sample size
was small in the newly diagnosed T2DM subgroup, the
heterogeneity was also small and a significant risk rela-
tionship between T2DM and CRA was still detected. A
similar result was only found in the advanced adenoma
subgroup, not in the proximal, distal, colon or multiple
adenoma subgroups. When low-quality studies were ex-
cluded, the positive association still existed. These re-
sults suggested that T2DM patients should pay more
attention to their risk of CRA.
The positive relationship between T2DM and CRA
may be linked to insulin resistance or an increased
Potential articles from databases (n=2522)
Abstracts and title excluded during first screening  (n=2409)      




24 articles have no reported  diabetes
32 articles have no desirable outcomes
9  articles reported  colorectal cancer  or neoplasm
Articles(n=14)  and conference abstract(n=3) included in meta-analysis 






Fig. 1 Flow chart of article selection process
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Table 1 Characteristic of studies included in the meta-analysis
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insulin-like growth factor 1 (IGF-1) might take effect in
the adenoma–carcinoma process. High insulin levels
could promote tumor growth [31, 45, 46]. Also, diabetes
may lead to slower bowel transit, which would increase
the probability of exposure to potential carcinogens for
colonic mucosa [47–49]. It is worth noting that there
might be some confounding effects because of the simi-
lar risk factors for both T2DM and CRA, such as phys-
ical inactivity, obesity, and an unhealthy diet habit [12,
50]. For example, a case–control study reported that
higher red meat intake could significantly increase the
risk of colon adenoma [51]. At the same time, obese
people also tend to consume more red meats and have a
higher risk of diabetes. Therefore, dietary habits might
be a confounding factors. Finally, some researchers also
report that obesity might be a confounder in the associ-
ation between T2DM and colorectal disease [52].
Some studies reported a difference in risk between
males and females [12, 39, 53–55]; however, the results
of our subgroup analysis showed no difference. One pos-
sible explanation involves the redistribution of body fat
that can occur when women experience menopause.
The increase in visceral body mass fat could lead to
hyperinsulinemia so that women, especially post-
menopausal women, are more susceptible to colorectal
diseases. However, the existence of menopause in some
women cannot explain the different CRC risks for males
and females [56–59]. Discrepancies among these studies
Table 1 Characteristic of studies included in the meta-analysis (Continued)
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Fig. 2 Forest plot of relative risk estimates of diabetes on risk of colorectal adenoma
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Table 2 Subgroup analyses for the effect of diabetes on risk of colorectal adenoma
Subgroup Sample
size
RR (95 % CI) P value Heterogeneity
χ2 I2 P value
Sub-site of adenoma
Advanced adenoma 2145 1.41 (1.06–1.87) 0.018 1.50 0.0 % 0.473
Proximal adenoma 9343 1.28 (0.88–1.87) 0.199 10.89 72.4 % 0.012
Distal adenoma 9343 1.11 (0.89–1.38) 0.353 3.63 17.3 % 0.305
Colon adenoma 11201 1.06 (0.73–1.53) 0.758 10.72 72.0 % 0.013
Multiple adenoma 6840 1.95 (0.97–3.94) 0.061 6.73 85.2 % 0.009
Type of diabetes
Known T2DM 20326 1.56 (1.16–2.08) 0.003 43.88 81.8 % 0.000
Newly diagnosed T2DM 1604 1.51 (1.16–1.97) 0.002 0.00 0.0 % 0.946
Gender
Male 7839 1.33 (0.99–1.80) 0.059 4.74 36.7 % 0.192
Female 5135 1.29 (0.76–2.17) 0.348 10.33 80.6 % 0.006
Area
Europe 13527 1.27 (1.02–1.57) 0.032 2.18 0.0 % 0.336
USA 5767 1.69 (1.14–2.51) 0.009 32.18 84.5 % 0.000
Asia 11684 1.57 (1.21–2.05) 0.001 13.23 62.2 % 0.021
Study type
Prospective study 13871 1.27 (0.77–2.10) 0.357 11.93 83.2 % 0.003
Retrospective study 17405 1.57 (1.30–1.89) 0.000 25.40 60.6 % 0.005
Population based study 6122 1.46 (1.21–1.89) 0.005 2.06 3 % 0.357
Studies with high quality 26046 1.64 (1.26–2.14) 0.000 45.78 78.2 % 0.000
T2DM type 2 diabetes mellitus
Fig. 3 Result of sensitivity analyses by omitting one study in each turn
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and ours and the insignificant results by adenoma sub-
site might be attributed to the limited sample sizes and
insufficient statistical power. For the prospective studies,
varied different follow-up procedures and mix of ethnici-
ties different study populations might be the sources of
heterogeneity.
Our analysis revealed that with T2DM have about a
5 % higher risk of CRA than newly diagnosed diabetes
patients, revealing the duration of T2DM as a risk factor
for CRA. A possible explanation is that known T2DM
patients’ bowels are exposed to hyperinsulinemia or a
hyperglycemic environment for a longer time, and such
hormonal or metabolic abnormalities (according to
former study [60]) could affect tumour growth. However,
some studies reported that metformin use was a protect-
ive factor of CRA [33] and cancer [61]. If this is true, di-
agnosed diabetes patients should have a lower risk of
adenomas than new patients, which is counter to our re-
sults. On the other hand, the severity of T2DM, which
was not confirmed in the included studies, may affect
colorectal disease risk and contribute to the mixed results.
In sum, there might be a dose–response relationship be-
tween insulin and CRA, and further studies should in-
clude this as an important potential confounding factor.
Several limitations of in this meta-analysis that should
be taken into consideration. First, results for several sub-
groups, such as gender and adenoma sub-site subgroup,
were based on a limited number of studies. Therefore,
we cannot rule out the possibility that insufficient statis-
tical power is present. Second, in the present analysis,
some small studies with inverse associations between
T2DM and risk of CRA risk seemed to be suppressed.
The presence of possible publication bias could have led
to an overestimation of the effect of T2DM on CRA risk.
However, the adjusted result was comparable after trim
and fill method corrections. Third, we could not account
for all of the confounding factors in the meta-analysis,
though most confounders were adjusted in the original
RRs. Many factors might induce the adenomas, such as
age, ethnicity, inactivity, regular aspirin use, obesity, and
family history of CRA, and menopausal status. We could
not control for these covariates because of lack of relevant
data. Relevant studies with additional data on these other
factors may be found by searching by searching beyond
the sources used for this study. Furthermore, we could
not determine whether using insulin as a therapy for
T2DM is an important factor because CRA risk might be
altered by hyperinsulinemia, thought to be an important
promoter of carcinogenesis [62, 63]. At the same time,
metformin may have a direct anti-proliferative effect [64].
Finally, most of the existing studies did not discuss the in-
fluences of T2DM severity level on CRA risk. Thus, more
cohort studies about these topics should be conducted.
Conclusions
In conclusion, the results of our meta-analysis indicated
that patients with T2DM have higher risks for the devel-
opment of CRA, which is an important inducement for
colorectal cancer. Our study has important implications
for clinical and public health. Because T2DM and CRA
are prevalent in the developed and developing countries
[65], medical workers should increase the rate of CRA
screening for T2DM patients so that they can benefit from
behavioural interventions that can help prevent CRA [38].
Large prospective studies that investigate the interactions
among environmental and behavioral factors, medications,
and functional polymorphisms are also needed to further
clarify the etiology of CRA.
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